Repare Therapeutics (RPTX) has filed a preliminary prospectus for its IPO of 10M common shares at $18 – 20 per share.
Two days ago, it filed the same for an initial public offering of ~7.4M shares at $16 – 18.
The Cambridge, MA-based biotech develops precision oncology treatments
based on synthetic lethality (SL), an approach to drug development
focused on genomic instability, including DNA damage repair. SL pertains
to a deficiency in either of two genes that is tolerated in cells, but
leads to cell death when both genes are present. The company employs its
proprietary, genome-wide, CRISPR-enabled SNIPRx platform to
identify and develop highly targeted therapeutics for tumors that
contain a mutation in one gene of an SL pair, making them prime
candidates for intervention by targeting the other gene in the pair.
https://seekingalpha.com/news/3583977-repare-therapeutics-files-for-upsized-ipo
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.